Free tool
FAERS Monitor: Lamictal
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 020241 or its brand name (Lamictal, Lamotrigine). Reports on generic versions are filed under their own applications.
Reports
131,733
Serious
95,211
72% of reports
Hospitalization
40,656
Death reported
11,487
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective10,332
- rash8,688
- seizure6,701
- nausea6,455
- off label use6,291
- fatigue6,259
- dizziness6,075
- headache5,812
- depression5,269
- vomiting4,846
- somnolence4,541
- pyrexia4,521
- drug interaction4,516
- anxiety4,496
- toxicity to various agents4,368
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 2,016 |
| 2005 | 3,052 |
| 2006 | 3,557 |
| 2007 | 3,880 |
| 2008 | 2,377 |
| 2009 | 4,888 |
| 2010 | 3,756 |
| 2011 | 4,923 |
| 2012 | 5,255 |
| 2013 | 4,635 |
| 2014 | 5,128 |
| 2015 | 7,165 |
| 2016 | 7,472 |
| 2017 | 7,202 |
| 2018 | 8,195 |
| 2019 | 8,572 |
| 2020 | 7,702 |
| 2021 | 7,239 |
| 2022 | 6,628 |
| 2023 | 6,979 |
| 2024 | 7,673 |
| 2025 | 7,869 |
| 2026 | 5,569 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,922,426 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| seizureSignal | 6,701 | 9.8 | 9.5 | 49,968 |
| drug interactionSignal | 4,516 | 4.6 | 4.5 | 12,657 |
| toxicity to various agentsSignal | 4,368 | 4.2 | 4.1 | 10,531 |
| depressionSignal | 5,269 | 3.8 | 3.7 | 10,545 |
| somnolenceSignal | 4,541 | 3.7 | 3.6 | 8,664 |
| rashSignal | 8,688 | 3.2 | 3.2 | 13,358 |
| anxietySignal | 4,496 | 2.5 | 2.5 | 4,212 |
| pyrexiaSignal | 4,521 | 2.1 | 2.0 | 2,615 |
| dizziness | 6,075 | 2.0 | 1.9 | 2,873 |
| vomiting | 4,846 | 1.7 | 1.6 | 1,263 |
| headache | 5,812 | 1.5 | 1.4 | 938 |
| nausea | 6,455 | 1.3 | 1.3 | 473 |
| fatigue | 6,259 | 1.3 | 1.3 | 409 |
| drug ineffective | 10,332 | 1.3 | 1.2 | 561 |
| off label use | 6,291 | 1.1 | 1.1 | 124 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.